SOLICITATION NOTICE
66 -- BD LSRII Special Edition Flow Cytometer
- Notice Date
- 12/10/2008
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90019-MM
- Archive Date
- 1/3/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen,, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR) plans to procure the brand name BD LSRII Special Edition Flow Cytometer with BD Biosciences, 2350 Qume Drive, San Jose, CA 95131. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 334516 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. The BD LSRII Special Edition cell analyzer will allow the NCI to have a Core instrument with a configuration that is compatible to the customized instruments in the Vaccine Research Center, NIAID. The BD LSRII Special Edition will be the only core instrument on the NCI Bethesda campus with a 532 nm laser and octagon optics necessary for the optimum use of readily-available PE-tandum dyes and a 405nm laser and octagon optics for the optimum use of Quantum dot technology. With its unique laser and detector combination, this instrument will complement rather than replicate the other LSRII currently in the Core. The Building 41 core will support the Vaccine Branch, the Laboratory of Receptor Biology and Gene Expression (LRBGE), the Laboratory of Cellular Oncology (LCO), and the new Stem Cell Laboratory. Facts and Reasons to Justify Other than Full and Open Competition 1.Statute Statute: 41 U.S.C. 253 (1) as set forth in FAR 13.106-(b)(2) and 13.501-(a)(1) (b) Solicitation from a single source. (2)For Sole source acquisition of commercial items in excess of the simplified acquisition threshold conducted pursuant to subpart 13.5, the requirements at 13.501(a) apply. No other requirement and/or type for supply or service will satisfy agency need. 2. Sole Source Justification: Salient characteristics which apply to the BD FACSAria II Cell Sorter: •Incorporates a cuvette/flow cell that is gel coupled to the fluorescence objective lens; •Incorporates cytometer setup and tracking (CS&T) software; •Uses Octagon and Trigon technology for fluorescence detection The BD LSR II Special Edition is the only known cell analyzer on the market designed for 16+ color analysis. This platform was designed with input from the Vaccine Research Center, NIAID to optimize multicolor analysis utilizing commercially available fluorescent dyes. Since all of the existing instruments in the NCI Flow Core facility are from BD Biosciences, it is in the best interest of the researchers to use the same platform when analyzing their samples. The BD LSRII Special Edition utilizes the same optical configuration as the BD LSRII and FACSCanto instruments currently in the facility. This allows for the use of the same reagents for analysis on multiple instruments. BD Biosciences is the only known source which has local field service engineer support in place (6 engineers) to be able to provide rapid response to NIH/NCI laboratories. This is a critical reason for choosing BD Biosciences as instrument uptime and fast time to repair are critical. The BD LSR II Special Edition is the only known instrument that meets all of the above requirements. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on December 19, 2008. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-90019-MM on all correspondence.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=c85f9c676e3ae75bf940730dcea96785&tab=core&_cview=1)
- Record
- SN01716939-W 20081212/081210221048-c85f9c676e3ae75bf940730dcea96785 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |